Skip to main content
GRAL
NASDAQ Industrial Applications And Services

GRAIL Q2 Revenue Jumps 26% on 35% Galleri Volume Surge; Samsung Deal Closes, Adding $110M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$64.97
Mkt Cap
$2.721B
52W Low
$29.95
52W High
$118.84
52W Position info
117% above low
Off High info
45% below high
Rel. Volume info
2.8× avg
Market data snapshot near publication time

GRAL has more than doubled off its 52-week low of $29.95 on elevated volume (2.8× avg).

Summary

GRAIL's Q2 revenue rose 26% to $44.7M on 35% Galleri volume growth. The $110M Samsung investment closed at a premium, but a $25.4M impairment and new lawsuits cloud the outlook.


Key Events · Earnings and Guidance · GRAL

  • Q2 Revenue Surges 26%

    Total revenue hit $44.7M, up from $35.5M a year ago, driven by a 35% increase in Galleri test volume to over 117,000 tests in H1 2026.

  • Samsung Strategic Investment Closes

    Completed $110M private placement at $70.05/share (a premium to today's $64.97), issuing 1.57M shares. Proceeds fund commercialization and working capital.

  • $25.4M Impairment on Samsung Deferred Asset

    The full deferred asset from the Samsung deal was written off as unrecoverable under the collaboration agreement, hitting Q2 earnings.

  • New Securities Class Action Filed

    A putative class action (Robbins v. GRAIL) alleges misleading statements about the NHS-Galleri trial. A related derivative suit (Augitto) was also filed.


Analysis · GRAL · Industrial Applications And Services

GRAIL delivered strong Q2 results with revenue up 26% to $44.7M, driven by a 35% jump in Galleri test volume following positive NHS-Galleri and PATHFINDER 2 data. The company closed its $110M Samsung strategic investment, adding 1.57M shares at $70.05 — a premium to the current $64.97 stock price — and extended its cash runway. However, a $25.4M impairment on the Samsung deferred asset and new securities class actions tied to the NHS-Galleri trial add risk. The combination of accelerating commercial traction, a major strategic partnership, and litigation overhang makes this a pivotal update for investors.

At the time of this filing, GRAL was trading at $64.97 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $29.95 to $118.84. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GRAL - Latest Insights

GRAL
Aug 05, 2026, 4:02 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $68.00
Real-time Price: $64.97 info
Change: -$3.03 (-4%) info
Market Cap: $2.721B info
GRAL
Jul 14, 2026, 6:17 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $71.80
Real-time Price: $64.97 info
Change: -$6.83 (-10%) info
Market Cap: $2.721B info
GRAL
Jun 29, 2026, 3:31 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $68.50
Real-time Price: $64.97 info
Change: -$3.53 (-5%) info
Market Cap: $2.721B info
GRAL
May 30, 2026, 8:14 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $73.00
Real-time Price: $64.97 info
Change: -$8.03 (-11%) info
Market Cap: $2.721B info
GRAL
May 07, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $61.72
Real-time Price: $64.97 info
Change: +$3.25 (+5%) info
Market Cap: $2.721B info